Tiziano Barbui

Summary

Affiliation: Ospedali Riuniti
Country: Italy

Publications

  1. ncbi request reprint Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk
    Tiziano Barbui
    Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 33:321-9. 2007
  2. doi request reprint Thrombosis in primary myelofibrosis: incidence and risk factors
    Tiziano Barbui
    Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 115:778-82. 2010
  3. doi request reprint Special issues in myeloproliferative neoplasms
    Tiziano Barbui
    Research Foundation, Ospedali Riuniti, Via Garibaldi 13, 24124, Bergamo, Italy
    Curr Hematol Malig Rep 6:28-35. 2011
  4. doi request reprint Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 120:5128-33; quiz 5252. 2012
  5. doi request reprint Front-line therapy in polycythemia vera and essential thrombocythemia
    Tiziano Barbui
    Department of Hematology, Ospedali Riuniti di Bergamo, Italy
    Blood Rev 26:205-11. 2012
  6. doi request reprint Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Blood 120:569-71. 2012
  7. doi request reprint How to manage children and young adults with myeloproliferative neoplasms
    T Barbui
    Hematology and Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Leukemia 26:1452-7. 2012
  8. doi request reprint Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Italy
    Blood 119:2239-41. 2012
  9. pmc Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
    Tiziano Barbui
    Hematology Department, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Haematologica 96:315-8. 2011
  10. doi request reprint How to manage thrombosis in myeloproliferative neoplasms
    Tiziano Barbui
    Department of Hematology and Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Curr Opin Oncol 23:654-8. 2011

Detail Information

Publications93

  1. ncbi request reprint Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk
    Tiziano Barbui
    Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 33:321-9. 2007
    ..The recent identification of JAK2V617F mutation in a substantial proportion of patients with PV and ET raises new questions regarding both risk classification and management, but additional studies on these issues are required...
  2. doi request reprint Thrombosis in primary myelofibrosis: incidence and risk factors
    Tiziano Barbui
    Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 115:778-82. 2010
    ....
  3. doi request reprint Special issues in myeloproliferative neoplasms
    Tiziano Barbui
    Research Foundation, Ospedali Riuniti, Via Garibaldi 13, 24124, Bergamo, Italy
    Curr Hematol Malig Rep 6:28-35. 2011
    ..This article reviews the state of the art regarding these issues, with special emphasis on experts' consensus recommendations...
  4. doi request reprint Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 120:5128-33; quiz 5252. 2012
    ..03% of patients/y versus 2.35% of patients/y versus 3.56% of patients/y, outperformed the 2-tiered (low-risk 0.95% of patients/y vs high-risk 2.86% of patients/y) conventional risk stratification in predicting future vascular events...
  5. doi request reprint Front-line therapy in polycythemia vera and essential thrombocythemia
    Tiziano Barbui
    Department of Hematology, Ospedali Riuniti di Bergamo, Italy
    Blood Rev 26:205-11. 2012
    ..ELN recommends to prescribe cytoreductive drugs in children as a last resort. No results of clinical trials with JAK-2 inhibitor drugs in PV and ET are so far available...
  6. doi request reprint Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Blood 120:569-71. 2012
    ..29% vs 3.43% of patients/year, P = .01) in WHO-ET and early PMF, respectively. In multivariate analysis, early PMF and the JAK2V617F mutation emerged as independent factors predicting cumulative adverse events...
  7. doi request reprint How to manage children and young adults with myeloproliferative neoplasms
    T Barbui
    Hematology and Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Leukemia 26:1452-7. 2012
    ..In the remaining young PMF patients palliative therapy or experimental drugs are considered...
  8. doi request reprint Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Italy
    Blood 119:2239-41. 2012
    ..The present study clarifies the incidence, degree, and prognostic relevance of bone marrow fibrosis obtained at time of initial diagnosis of polycythemia vera...
  9. pmc Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
    Tiziano Barbui
    Hematology Department, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Haematologica 96:315-8. 2011
    ....
  10. doi request reprint How to manage thrombosis in myeloproliferative neoplasms
    Tiziano Barbui
    Department of Hematology and Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Curr Opin Oncol 23:654-8. 2011
    ..In this article, an updated overview of risk factors and management of vascular complications in myeloproliferative neoplasms (MPN) is presented...
  11. ncbi request reprint Evidence-based management of polycythemia vera
    Tiziano Barbui
    Department of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy
    Best Pract Res Clin Haematol 19:483-93. 2006
    ..This chapter provides updated estimates of the risk of thrombosis and disease progression and evaluates the various randomized and observational studies in polycythemia vera, according to an evidence-based approach...
  12. pmc Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?
    Tiziano Barbui
    Hematology Division, Ospedali Riuniti, Largo Barozzi 1, Bergamo, Italy
    Blood 114:759-63. 2009
    ..Until such evidence is available, the decision on how to manage these patients should continue to follow conventional criteria...
  13. ncbi request reprint Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Haematologica 90:1643-9. 2005
    ....
  14. doi request reprint Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
    Alessandra Carobbio
    Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Blood 117:5857-9. 2011
    ..The current study clarifies the contribution of specific disease and host characteristics to the risk of arterial versus venous thrombosis in essential thrombocythemia...
  15. ncbi request reprint Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
    Tiziano Barbui
    Divisione di Ematologia Spedali Riuniti, Bergamo, Italy
    Haematologica 89:215-32. 2004
    ....
  16. ncbi request reprint Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma
    Alessandro Rambaldi
    Divisione di Ematologia, Ospedali Riuniti Largo Barozzi 1, 24100, Bergamo, Italy
    Blood 105:3428-33. 2005
    ..006). RQ-PCR performed at presentation on BM samples predicts treatment response and long-term clinical outcome in patients with follicular lymphoma...
  17. pmc Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia
    Alessandra Carobbio
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 112:3135-7. 2008
    ..These data challenge the theory that elevated platelet count increases thrombosis risk in ET and suggest prospective clinical trials to support this hypothesis...
  18. ncbi request reprint Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups
    Renato Bassan
    Division of Haematology, Cytogenetics Unit, Ospedali Riuniti, Bergamo, Italy
    Hematol J 3:193-200. 2002
    ..An exploratory trial was conducted to evaluate toxicity and potential therapeutic role of all trans-retinoic acid (ATRA) given long-term together with chemotherapy and G-CSF to adult patients with acute myelogenous leukemia (AML)...
  19. ncbi request reprint Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 110:1178-83. 2007
    ..They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection...
  20. doi request reprint Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria
    Alessandra Carobbio
    Hematology Department, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Blood 116:1051-5. 2010
    ..The actuarial probability of thrombosis was significantly influenced by leukocytosis (P = .017) and not by platelet count, indicating that platelet number does not seem of prime relevance in the definition of ELN response...
  21. ncbi request reprint Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia
    Orietta Spinelli
    Hematology and Bone Marrow Transplantation Units of Ospedali Riuniti Bergamo, Bergamo, Italy
    Haematologica 92:612-8. 2007
    ..The aim of this study was to correlate the kinetics of MRD clearance after allogeneic transplantation with the clinical outcome of adults with ALL...
  22. ncbi request reprint Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, 50134 Florence, Italy
    Blood 110:840-6. 2007
    ..We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET...
  23. doi request reprint Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
    Renato Bassan
    Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Blood 113:4153-62. 2009
    ..001) using a level of 10(-4) or higher to define persistent disease. MRD analysis during early postremission therapy improves risk definitions and bolsters risk-oriented strategies. ClinicalTrials.gov identifier: NCT00358072...
  24. doi request reprint Leukocytosis and risk stratification assessment in essential thrombocythemia
    Alessandra Carobbio
    Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Clin Oncol 26:2732-6. 2008
    ..Established risk factors for thrombosis in essential thrombocythemia (ET) include age and previous vascular events. We aimed to refine this risk stratification by adding baseline leukocytosis...
  25. ncbi request reprint Masked polycythemia vera diagnosed according to WHO and BCSH classification
    Tiziano Barbui
    Papa Giovanni XXIII hospital, Bergamo, Italy
    Am J Hematol 89:199-202. 2014
    ..This study has established the existence of mPV by two different classification systems based on either HB or HCT threshold values. Am. J. Hematol. 89:199-202, 2014. © 2013 Wiley Periodicals, Inc. ..
  26. ncbi request reprint Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study
    Tiziano Barbui
    Ospedali Riuniti di Bergamo, Bergamo, Italy
    J Clin Oncol 29:3179-84. 2011
    ..This study examined the clinical relevance of such a distinction...
  27. pmc JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera
    Alessandra Carobbio
    Hematology Department, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Exp Hematol 37:1016-21. 2009
    ..A direct comparison of the incidence and risk factors of major thrombosis in essential thrombocythemia (ET) and polycythemia vera (PV) according to their respective JAK2V617F allele burden is the object of this study...
  28. doi request reprint Masked polycythemia vera (mPV): results of an international study
    Tiziano Barbui
    Papa Giovanni XXIII hospital, Bergamo, Italy
    Am J Hematol 89:52-4. 2014
    ....
  29. ncbi request reprint Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey
    Marco Ruggeri
    Department of Hematology, San Bortolo Hospital, Vicenza, Italy
    Blood 111:666-71. 2008
    ..A high proportion of PV and ET surgeries was complicated by vascular occlusion (7.7%) or by a major hemorrhage (7.3%). Prospective investigations analyzing the optimal prophylaxis in these patients are suggested...
  30. doi request reprint Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia
    Alessandra Carobbio
    Division of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Am J Hematol 87:203-4. 2012
    ....
  31. ncbi request reprint The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Tiziano Barbui
    Department of Hematology, Ospedali Riuniti di Bergamo, Italy
    Semin Hematol 41:15-7. 2004
    ..However, no controlled clinical trials of efficacy and safety are available for these two drugs and the occurrence of side effects may be a limiting factor for their widespread use...
  32. ncbi request reprint V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules
    Anna Falanga
    Department of Hematology Oncology, Ospedali Riuniti, Bergamo, Italy
    Exp Hematol 35:702-11. 2007
    ....
  33. doi request reprint A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes
    Tamara Intermesoli
    Unità Strutturale Complessa di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 147:681-5. 2009
    ..Low-dose, short-course imatinib may represent a rational choice for identifying responsive cases, both within and outside the pre-defined FIP1L1 rearrangement subset...
  34. doi request reprint A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
    Alessandro Rambaldi
    Haematology, Ospedali Riuniti di Bergamo, Largo Barozzi, Bergamo, Italy
    Br J Haematol 150:446-55. 2010
    ..Reverse transcription polymerase chain reaction identified a trend to reduction of the JAK2V617F allele burden. Givinostat was well tolerated and could induce haematological response in most PV and some MF patients...
  35. doi request reprint Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms
    Giuseppe Cella
    Division of Immunohematology and Transfusion Medicine and Hemostasis and Thrombosis Center, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 104:151-6. 2010
    ..Our data demonstrate that ET and PV are characterised by an altered pattern of soluble selectins and NOX. HU-mediated increase of NOX levels could represent an additional antithrombotic mechanism of this drug...
  36. ncbi request reprint Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome
    Monica Galli
    Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Blood 102:2717-23. 2003
  37. ncbi request reprint Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin
    Marina Marchetti
    Department of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi, 1 24128 Bergamo, Italy
    Thromb Res 121:637-45. 2008
    ..Clinical studies suggest a survival advantage in cancer patients receiving low molecular weight heparin (LMWH). A suggested mechanism for this beneficial effect may reside in the antiangiogenic activity of heparins...
  38. ncbi request reprint Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
    Alessandra Carobbio
    Divisione di Ematologia, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 109:2310-3. 2007
    ..We suggest validation of these findings in prospective clinical studies...
  39. ncbi request reprint Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 129:240-7. 2005
    ..Most, although not all, IgG containing anti-prothrombin antibodies inhibit the APC-catalysed FVa inactivation, which may contribute to the increased risk of thrombosis in patients with the anti-phospholipid syndrome...
  40. ncbi request reprint Antiphospholipid antibodies in lymphoma: prevalence and clinical significance
    Simona Pusterla
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Hematol J 5:341-6. 2004
    ..In conclusion, antiphospholipid antibodies are associated with lymphomas. Their determination is useful to identify patients at high risk to develop thrombotic complications, but not to predict treatment outcome or disease prognosis...
  41. doi request reprint Hypercoagulability and tissue factor gene upregulation in hematologic malignancies
    Anna Falanga
    Department Hematology Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Semin Thromb Hemost 34:204-10. 2008
    ..Understanding the pathophysiology of hypercoagulability is critical to the design of appropriate measures for intervention in these hematologic disorders to prevent thromboembolic complications...
  42. ncbi request reprint Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests
    Monica Galli
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 31:17-24. 2005
    ..Many efforts are currently being made to improve assay standardization and harmonization, which should help to clarify the clinical relevance of antiphospholipid antibodies...
  43. doi request reprint Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera
    Marina Panova-Noeva
    Division of Immunohematology and Transfusion Medicine, Ospedali Riuniti di Bergamo, Largo Barozzi 1, Bergamo, Italy
    Am J Hematol 86:337-42. 2011
    ..05).This study demonstrates a platelet-dependent form of hypercoagulability in MPN patients, particularly in those carriers of the JAK2V617F mutation. The cytoreductive therapy with HU significantly affects this prothrombotic phenotype...
  44. ncbi request reprint Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia
    Tiziano Barbui
    Division of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Curr Hematol Rep 2:248-56. 2003
    ..Furthermore, interferon and anagrelide have frequent and clinically important side effects. Thus, further clinical studies are required to establish their role in the management of patients with ET...
  45. ncbi request reprint All-trans-retinoic acid and bleeding/thrombosis
    Anna Falanga
    Hematology Oncology Department, Ospedali Riuniti, Bergamo, Italy
    Pathophysiol Haemost Thromb 33:19-21. 2003
  46. ncbi request reprint Are MPNs vascular diseases?
    Guido Finazzi
    Division of Hematology, Ospedale Papa Giovanni XXIII, Piazza OMS, 1, 24127, Bergamo, BG, Italy
    Curr Hematol Malig Rep 8:307-16. 2013
    ..Phlebotomy and myelosuppressive agents are the current therapeutic options for correcting these abnormalities and reducing thrombosis in this special vascular disease represented by MPN...
  47. doi request reprint A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
    Guido Finazzi
    Haematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
    Br J Haematol 161:688-94. 2013
    ..The combined use of Givinostat and HC was safe and clinically effective in HC-unresponsive PV patients...
  48. ncbi request reprint Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils
    Anna Falanga
    Hematology Division, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Semin Hematol 42:239-47. 2005
    ..Available data suggest that these hemostatic markers deserve to be included in prospective clinical studies aimed at identifying their predictive role in the vascular complications of patients with ET and PV...
  49. ncbi request reprint Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties
    Alfonso Vignoli
    Department of Hematology Oncology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy
    Haematologica 91:207-14. 2006
    ..e. dalteparin, with UFH on both microvascular (human microvascular endothelial cells [HMEC-1]) and macrovascular (human umbilical vein endothelial cells [HUVEC]) endothelial cells...
  50. ncbi request reprint Antiphospholipid antibodies and pregnancy
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Largo Barozzi 1, 24128 Bergamo, Italy
    Best Pract Res Clin Haematol 16:211-25. 2003
    ..However, there is still an excessive frequency of maternal and/or fetal complications, indicating the necessity of a better calibration of the dosage, duration and timing of administration of heparin treatment...
  51. ncbi request reprint Indications for lowering platelet numbers in essential thrombocythemia
    Tiziano Barbui
    Department of Hematology, Ospedali Riuniti de Bergamo, Bergamo, Italy
    Semin Hematol 40:22-5. 2003
    ..4 x 10(9)/L, adding to the evidence that reduction of platelet counts to normal may be required for optimal control of risk...
  52. ncbi request reprint Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
    Anna Falanga
    Department of Hematology Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Exp Hematol 33:523-30. 2005
    ..We want to define whether this phenomenon plays a role in the formation of circulating PMN-platelet aggregates in these conditions...
  53. ncbi request reprint Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
    Tiziano Barbui
    Research Foundation, Papa Giovanni XXIII hospital, Bergamo, Italy Division of Hematology, Papa Giovanni XXIII hospital, Bergamo, Italy
    Am J Hematol 89:588-90. 2014
    ..For HCT, this was 49% in males and 48% in females. The proportion of patients correctly classified as ET or PV when regarding Hb or HCT levels was 95% in males and 93% in females and 94% in both males and females, respectively...
  54. ncbi request reprint Expertise-based management in essential thrombocythemia and polycythemia vera
    Guido Finazzi
    Department of Transfusion Medicine, Ospedali Riuniti, Bergamo, Italy
    Cancer J 13:372-6. 2007
    ..The recent identification of the JAK2 V617F mutation in a substantial proportion of patients with PV and ET raises the possibility of a molecularly targeted therapy...
  55. ncbi request reprint Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by short-course cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia
    Renato Bassan
    Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy
    Haematologica 87:257-63. 2002
    ..The principal aim was to define the maximum tolerated dose (MTD) of IDR, which is reported to be a less MDR1-sensitive anthracycline. The short CsA infusion was patterned after the results of a previous in vitro study...
  56. ncbi request reprint Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study
    Sara Previtali
    Department of Hematology, Ospedali Riuniti, Bergamo, Italy
    Thromb Haemost 88:729-32. 2002
    ..Their measurement, therefore, is not warranted in the laboratory screening of patients with arterial and/or venous thrombosis...
  57. ncbi request reprint Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma
    Anna Maria Barbui
    Divisione di Ematologia, Radioterapia and Centro Trasfusionale, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 116:202-10. 2002
    ..This suggests that autologous transplantation using efficiently purged PBSCs can be performed safely, but confirms the need for innovative protocols for MRD eradication in vivo...
  58. ncbi request reprint Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature
    Monica Galli
    Division of Hematology, Ospedali Riuniti, Bergamo, Italy
    Blood 101:1827-32. 2003
    ..However, to take full advantage of the conclusions provided by the available evidence, there is an urgent need to harmonize investigational methods...
  59. ncbi request reprint Risk-adapted therapy in essential thrombocythemia and polycythemia vera
    Guido Finazzi
    Department of Hematology, Ospedali Riuniti de Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy
    Blood Rev 19:243-52. 2005
    ..New therapeutic options, theoretically devoid of leukemic risk, such as alpha-interferon, anagrelide and imatinib should be reserved to selected patients and require further clinical experience...
  60. ncbi request reprint Antiphospholipid antibodies and thrombosis: strength of association
    Monica Galli
    Department of Hematology, Ospedali Riuniti, Largo Barozzi 1, Bergamo 24128, Italy
    Hematol J 4:180-6. 2003
    ..Upon treatment, the live birth rate increases from 0-40% to 70-80%...
  61. ncbi request reprint Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
    Martino Introna
    Laboratory of Cellular and Gene Therapy G Lanzani, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Haematologica 92:952-9. 2007
    ..The safety of these cells in autologous settings has been shown. We performed a phase I study of allogeneic (donor's) CIK cells in patients relapsing after allogeneic haematopoietic stem cell transplantation (HSCT)...
  62. ncbi request reprint Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome
    Gianpietro Dotti
    Division of Hematology, Ospedali Riuniti of Bergamo, Bergamo, Italy
    Transplantation 74:1095-102. 2002
    ..The clinical outcome and the best management for patients who present with late PTLDs still remain unclear...
  63. ncbi request reprint How I treat patients with polycythemia vera
    Guido Finazzi
    Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 109:5104-11. 2007
    ..The demonstration of JAK2 V617F mutation in the vast majority of PV patients opens the avenue for the development of promising new molecularly targeted drugs...
  64. ncbi request reprint What is the standard treatment in essential thrombocythemia
    Tiziano Barbui
    Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy
    Int J Hematol 76:311-7. 2002
    ..Controlled clinical studies showing a benefit in preventing thrombotic and hemorrhagic complications are urgently needed...
  65. ncbi request reprint Antiphospholipid syndrome: definition and treatment
    Monica Galli
    Department of Haematology, Ospedali Riuniti, Bergamo, Italy
    Semin Thromb Hemost 29:195-204. 2003
    ....
  66. ncbi request reprint The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis
    Josee Golay
    Laboratory of Cellular and Gene Therapy G Lanzani, Division of Haematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Haematologica 91:322-30. 2006
    ..Campath-1H is used in conditioning regimens and more recently as an anti-leukemic therapy in acute lymphoblastic leukemias (ALL). We therefore investigated CD52 expression and campath-1H-mediated lysis of ALL cells in vitro...
  67. doi request reprint Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
    Corrado Girmenia
    Department of Hematology, Policlinico Umberto I, University of Sapienza, Rome, Italy
    Clin Infect Dis 49:1226-36. 2009
    ....
  68. ncbi request reprint Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma
    Alessandro Rambaldi
    Divisione di Ematologia, Ospedali Riuniti Bergamo, Largo Barozzi 1, 24100 Bergamo, Italy
    Blood 99:856-62. 2002
    ..001)...
  69. ncbi request reprint The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies
    Sergio Cortelazzo
    Divisione di Ematologia e Servizio di Anatomia Patologica e Citologia, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Br J Haematol 118:218-28. 2002
    ..This retrospective study shows that stage-MIPI can be a reliable prognostic indicator for PIL of both low-grade MZL and diffuse large B-cell histology, enabling the early identification of patients at higher risk of failure...
  70. ncbi request reprint All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties
    Marina Marchetti
    Hematology Department, Ospedali Riuniti Bergamo, Largo Barozzi, 1, 24128 Bergamo, Italy
    Haematologica 88:895-905. 2003
    ..In this study we investigated whether ATRA may affect the same activities of EC derived from microvessels (HMEC-1 cell line)...
  71. ncbi request reprint Idiopathic erythrocytosis and other non-clonal polycythemias
    Guido Finazzi
    Division of Hematology, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24128 Bergamo, Italy
    Best Pract Res Clin Haematol 19:471-82. 2006
    ..Phlebotomy in patients with IE is controversial. Myelosuppressive drugs should be avoided since their use is associated with evolution into acute leukemia in about 10% of patients...
  72. ncbi request reprint High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients
    Corrado Tarella
    Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Torino, Italy
    Cancer 97:2748-59. 2003
    ....
  73. ncbi request reprint Efficacy and safety of low-dose aspirin in polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Rome, Italy
    N Engl J Med 350:114-24. 2004
    ..The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial...
  74. ncbi request reprint The haematocrit and platelet target in polycythemia vera
    Marcello Di Nisio
    Department of Medicine and Aging, School of Medicine, and Aging Research Centre, Ce S I, Gabriele D Annunzio University Foundation, Chieti Pescara, Italy
    Br J Haematol 136:249-59. 2007
    ..Our findings do not suggest that the range of haematocrit (<55%) and platelet counts (<600 x 10(9)/l) we encountered in our population had an impact on the outcome of PV patients treated by current therapeutic strategies...
  75. ncbi request reprint Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
    Guido Finazzi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Blood 105:2664-70. 2005
    ..84-16.25; P = .0023), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; P = .8021), had an independent role in producing an excess risk for progression to AML/MDS compared with treatment with phlebotomy or interferon...
  76. ncbi request reprint Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    Roberto Marchioli
    European Collaboration on Low Dose Aspirin in Polycythemia Vera Coordinating Centre, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    J Clin Oncol 23:2224-32. 2005
    ..The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments...
  77. ncbi request reprint Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
    Alessandro M Gianni
    Division of Medical Oncology C Donazione Cristina Gandini, Istituto Nazionale Tumori, Milan, Italy
    Blood 102:749-55. 2003
    ..The R-HDS regimen can be safely applied in a multicenter hematology setting and leads to long-term EFS and OS in the majority of patients with an otherwise incurable disease...
  78. ncbi request reprint When and how to treat essential thrombocythemia
    Tiziano Barbui
    N Engl J Med 353:85-6. 2005
  79. ncbi request reprint Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients
    Eros Di Bona
    Department of Haematology, Vicenza Hospital, Vicenza, Italy
    Leuk Lymphoma 46:879-84. 2005
    ..In spite of 12 HSCTs, there was no long-term survivor. 'ABC' salvage proved feasible and comparable to reported rescue chemotherapic regimens, but the achievement of cure in refractory/relapsing ALL remains an outstanding clinical task...
  80. doi request reprint Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    Valerio De Stefano
    Institute of Hematology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 93:372-80. 2008
    ..Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of re-thrombosis and the optimal strategy for prevention of recurrence...
  81. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  82. ncbi request reprint Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Institute of Internal Medicine and Geriatrics, Haemostasis Research Center, Rome, Italy
    Blood 109:2446-52. 2007
    ..71; 95% CI, 1.10-2.65; P = .017), mainly deriving from an increased risk of myocardial infarction (HR, 2.84; 95% CI, 1.25-6.46; P = .013). Thus, leukocyte count may help in defining the vascular risk of polycythemic subjects...
  83. doi request reprint Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey
    Corrado Tarella
    Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Az Osp S Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 26:3166-75. 2008
    ..To investigate the impact of adding rituximab to intensive chemotherapy with peripheral-blood progenitor cell (PBPC) autograft for high-risk diffuse large B-cell lymphoma (DLB-CL) and follicular lymphoma (FL)...
  84. ncbi request reprint Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis
    Guido Finazzi
    Blood 101:3749. 2003
  85. ncbi request reprint Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia
    Emanuela Carlotti
    Divisione di Ematologia, Ospedali Riuniti Bergamo, Clinica Paediatrica, Universita di Milano Bicocca, Ospedale S Gerardo, Monza, Italy
    Br J Haematol 118:1011-8. 2002
    ..By searching GenBank, we identified PAC RP1-18D14 which contains SIL, TAL-1 and 633-DNA, confirming this novel rearrangement as a new deletion of the SIL/TAL-1 locus...
  86. ncbi request reprint Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?
    Martino Introna
    Haematologica 88:482-4. 2003
  87. ncbi request reprint Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma
    Monica Galli
    Haematologica 89:1141-2. 2004
    ..1%; annual rate 7.25%), and another 14 events occurred in patients not on erythropoietin (9.3%; 7.56%). Thus, erythropoietin would seem not to increase the risk of thrombosis of myeloma patients receiving thalidomide...
  88. ncbi request reprint Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases
    Nicola Vianelli
    Hematology and Oncology Institute L and A Seràgnoli, University of Bologna
    Haematologica 90:72-7. 2005
    ..For these and for selected patients with acute refractory ITP, splenectomy may produce a good response (CR+PR) in about 60-80% of cases. We report here the long-term outcome of a large cohort of ITP splenectomized patients...
  89. ncbi request reprint Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study
    Agostino Cortelezzi
    Department of Haematology and Bone Marrow Transplantation Unit, IRCCS Fondazione Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
    Br J Haematol 129:811-7. 2005
    ..This study shows that the impact on clinical practice of symptomatic CVC-related thrombotic complications is not negligible in patients with haematological malignancies...
  90. ncbi request reprint Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group
    Tapani Ruutu
    Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
    Haematologica 92:95-100. 2007
    ..An International Working Group was formed to develop a consensus formulation of criteria for diagnosing clinically significant TAM...
  91. ncbi request reprint Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
    Guido Finazzi
    Haematologica 92:135-6. 2007
    ..The rate of thrombotic complications in JAK2-positive ET patients was significantly higher than that in wild-type ET patients and not statistically different from that in PV patients...
  92. doi request reprint Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
    Alessandro M Vannucchi
    Unita Funzionale di Ematologia, Dipartimento di Area Critica Medico Chirurgica, Universita degli Studi, Florence, Italy
    Blood 112:844-7. 2008
    ..These data indicate that MPLW515L/K mutations do not define a distinct phenotype in ET, although some differences depended on the JAK2V617F mutational status of the counterpart...
  93. ncbi request reprint JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
    Giovanni Barosi
    Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    Blood 110:4030-6. 2007
    ..We conclude that JAK2 V617F genotype should be considered in any future risk stratification of patients with PMF...